+ regulatory T cells (Tregs) and natural killer group 2, member D (NKG2D)-positive natural killer (NK) cells are considered to be important in the immune escape of colorectal cancer (CRC). However, the association between these two variables remains obscure. Therefore, in the present study, the levels of peripheral Tregs and NKG2D expression in NK cells and the associations in CRC patients were investigated. A total of 35 CRC patients and 16 healthy controls were enrolled in this study. Flow cytometry was performed to assay Treg numbers and NKG2D expression levels in NK cells in peripheral blood samples. Serum carcino-embryonic antigen (CEA) protein was assayed by electrochemiluminescence. Peripheral Treg numbers were significantly increased (P<0.05), while NKG2D expression levels in NK cells were significantly reduced (P<0.01) in CRC patients compared with healthy controls. However, no significant differences were identified in Treg numbers between CRC patients with and without lymph node metastases and between CRC patients with different clinical stages of CRC. Similarly, no significant differences were detected in NKG2D expression levels in NK cells between the different patient groups. Statistical analysis revealed that increased Treg numbers were not correlated with reduced NKG2D expression levels in NK cells from CRC patients. In addition, no statistical correlation was observed between Treg numbers and serum CEA protein in CRC patients. In conclusion, the upregulation of Tregs was not significantly correlated with the downregulation of NKG2D expression in NK cells in peripheral blood from CRC patients.
Introduction

CD4
+ CD25 + regulatory T cells (Tregs) are a specific subset of CD4 + T cells, and it has been suggested that Tregs are important in maintaining immune self-tolerance and in tumor immune escape (1) . Forkhead box protein 3 (Foxp3) has been identified as a CD4
+ CD25 + T cell-specific transcription factor and has been shown to be widely expressed in this cell type. Notably, Foxp3 regulates the development and function of Tregs. A number of studies have observed that Tregs may suppress the functions of CD8 + T cells, natural killer (NK) cells, natural killer T (NKT) cells and dendritic cells by cell contact and transforming growth factor-β-dependent mechanisms (1) (2) (3) (4) (5) (6) (7) (8) and that depletion of Tregs may result in effective antitumor immune responses (9) (10) (11) (12) . Patients with different types of cancer, including colorectal, ovarian, prostate and hepatocellular cancer, exhibit increased numbers of Tregs in the peripheral blood and tumor microenvironment; notably, the number of Tregs may have significant prognostic importance (13) (14) (15) (16) (17) (18) . Thus, Treg-targeting agents are currently being investigated in clinical trials and are a promising approach for cancer treatment (19) (20) (21) A number of studies have demonstrated that NKG2D is critical for tumor surveillance (22) (23) (24) (25) (26) . In a previous study, NKG2D expression levels were found to be significantly downregulated in NK cells collected from the peripheral blood of patients with colorectal cancer (CRC) and inhibition of the NKG2D signaling pathway with anti-NKG2D antibodies resulted in notably reduced cytotoxicity as well as CD107a degranulation in ex vivo experiments. Thus, reduced NKG2D expression levels may be associated with the suppression of NK cell activity in CRC (27) . Although the key role of Tregs as an immunosuppressive cell population is widely accepted, the association between Tregs and NKG2D expression levels in NK cells in CRC requires evaluation. In the present study, peripheral Treg numbers and NKG2D expression levels in NK cells were assayed in parallel using flow cytometry and the association between these variables in CRC patients was determined.
Materials and methods
Patients and controls.
A total of 35 patients (18 males and 17 females) with primary CRC and 16 healthy donors (8 males and 8 females) were enrolled in this study. Patients were hospitalized in the gastrointestinal surgery ward of Shandong Provincial Hospital Affiliated to Shandong University (Jinan, China). The CRC diagnosis in these patients was performed according to the Colorectal Cancer Diagnosis Standard (2010) issued by the Ministry of Health, China. The patients were classified as limited CRC or metastatic CRC according to whether lymph node metastases were present. As determined by clinical classification, the patients were stratified into early and advanced CRC. No patients had received chemotherapy and/or radiotherapy prior to sample collection. The clinical characteristics of the enrolled subjects are summarized in Table I . Informed consent was obtained from each participant. The protocol was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University.
Flow cytometry. Tregs were assayed with a regulatory T cell kit (eBioscience, San Diego, CA, USA) according to the manufacturer's instructions. For surface antigen staining, fluorescein isothiocyanate-conjugated anti-human CD4 and allophycocyanin (APC)-conjugated anti-human CD25 antibodies (eBioscience) were added to 100 µl whole blood and incubated for 30 min in the dark at 4˚C. Subsequently, 1X red blood cell (RBC) lysis buffer (eBioscience) was added to whole blood samples at room temperature in order to lyse RBCs. For intracellular antigen staining, fixation/permeabilization working solution (eBioscience) was added to the cells and incubated for 60 min in the dark prior to staining the cells with phycoerythrin (PE)-conjugated anti-human Foxp3 antibodies (eBioscience). Isotype controls were also run in parallel.
For detecting the NKG2D expression levels in NK cells, PE-conjugated anti-human CD3 (BD Biosciences, Missisauga, ON, Canada), APC-conjugated anti-human CD56 (BD Biosciences) and Alexa Fluor 488-conjugated anti-human NKG2D (R&D Systems, Minneapolis, MN, USA) antibodies were used. Isotype controls were concurrently run.
At least 10,000 cells were analyzed using a BD FACS Canto II flow cytometer (BD Biosciences).
Serum carcino-embryonic antigen (CEA) assay. Serum CEA protein in CRC patients was routinely assayed using the electrochemiluminescence method with a Roche Cobas e601 system (Roche Diagnostics, Mannheim, Germany) at the Department of Medical Biochemistry, Shandong Provincial Hospital Affiliated to Shandong University. In healthy subjects, CEA<10 ng/ml was considered to indicate a normal level of CEA.
Statistical analysis. The data were analyzed using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). Student's t-test was used for comparing quantitative variables between two groups. Spearman correlation analysis was performed to determine associations between two variables. P<0.05 was considered to indicate a statistically significant difference. Fig. 1A and B) . While no statistically significant difference was observed in Treg numbers between patients with limited and metastatic CRC, the data revealed a tendency for the number of Tregs to be higher in metastatic CRC than in limited CRC (8.233±1.008 vs. 6.435±0.4896, respectively; P>0.05; Fig. 1C) . Similarly, no significant difference was identified in the Treg numbers between early and advanced CRC patients (data not shown). Fig. 4A and B) . However, no differences in NKG2D expression levels were observed between NK cells collected from limited and metastatic CRC patients (Fig. 4C) . Fig. 6 ). However, in advanced CRC patients, elevated Treg numbers and CEA levels were observed (data not shown). Due to the small sample size of the present study, the possibility that these two variables are correlated in advanced CRC patients cannot be ruled out.
Results
CD4
Discussion
Since Foxp3 is considered to be the best marker of naturally occurring Tregs (2-4), the two CD4 + CD25 + Foxp3 + and CD4 + CD25 high Foxp3 + populations were defined as Tregs. In the present study, a significant increase in Treg numbers was observed in peripheral blood from CRC patients compared with the numbers of Treg cells in healthy controls (P<0.05), which is in accordance with a previous study (13) . However, no statistically significant difference in Treg numbers between CRC patients with and without lymph node metastases was identified, although increased Treg numbers in CRC patients with lymph node metastases were observed. Similarly, no significant difference was found in Treg numbers from patients with different clinical stages of CRC (data not shown). However, certain studies have reported that increased frequency of Tregs in peripheral blood and enhanced numbers of tumor-filtrating lymphocytes have marked prognostic significance in CRC (13) (14) (15) . Another study has demonstrated that accumulation of Tregs in draining lymph nodes is correlated with disease progression in CRC (28 (29, 30) . NKG2D is a predominant activating receptor in NK cells. As previously reported, the NKG2D receptor is critical for immunosurveillance of primary tumors in mouse models (24, 26) . A previous study suggested that decreased expression levels of NKG2D may be involved in the suppression of NK activity in CRC (27) . Another study observed that depletion of Tregs enhanced NK cell-mediated suppression of tumors expressing NKG2D ligands in a Rae1
+ experimental metastatic mouse model (31) . The Treg cells were able to suppress NK cell-mediated cytolysis of Rae1 + target cells in vitro. Therefore, Tregs may inhibit the cytotoxicity of NK cells via an NKG2D-NKG2D ligand pathway. However, in the present study, no significant correlation was identified between peripheral Treg numbers and NKG2D expression levels in NK cells collected from CRC patients. 
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As a nonspecific tumor marker, serum CEA protein is commonly increased in CRC patients and regularly serves as a treatment response and prognostic indicator for CRC (32, 33) . Nevertheless, in the present study, no correlation between Treg numbers and serum CEA protein levels in CRC patients was observed.
In conclusion, the results of the present study demonstrated that the number of peripheral Tregs was upregulated in CRC, but was not correlated with lymph node metastasis or clinical stage. Additionally, NKG2D expression was found to be downregulated in NK cells collected from patients with CRC, but was not correlated with lymph node metastasis. No significant correlations were identified between increased Treg numbers and reduced NKG2D expression levels in NK cells in CRC patients. Similarly, no significant correlations between peripheral Treg numbers and serum CEA levels were observed. Therefore, further studies are required to clarify the mechanisms through which Tregs and NKG2D may regulate immune escape in CRC.
